• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series.

作者信息

Caillard Sophie, Thaunat Olivier, Benotmane Ilies, Masset Christophe, Blancho Gilles

机构信息

Department of Nephrology and Transplantation, University Hospitals of Strasbourg, INSERM Unit 1109, Strasbourg, France.

Department of Transplantation Nephrology and Clinical Immunology, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, INSERM Unit 1111, Lyon, France.

出版信息

Ann Intern Med. 2022 Mar;175(3):455-456. doi: 10.7326/L21-0598. Epub 2022 Jan 11.

DOI:10.7326/L21-0598
PMID:35007148
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8754215/
Abstract
摘要

相似文献

1
Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series.肾移植受者对第四剂信使核糖核酸新冠疫苗的抗体反应：病例系列
Ann Intern Med. 2022 Mar;175(3):455-456. doi: 10.7326/L21-0598. Epub 2022 Jan 11.
2
Fourth dose of the SARS-CoV-2 vaccine in kidney transplant recipients with previously impaired humoral antibody response.先前体液抗体反应受损的肾移植受者接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗第四剂。
Am J Transplant. 2022 Nov;22(11):2704-2706. doi: 10.1111/ajt.17091. Epub 2022 May 19.
3
Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.肾移植受者对 SARS-CoV-2 mRNA 疫苗的抗体反应：一项前瞻性队列研究。
Clin Microbiol Infect. 2021 Aug;27(8):1173.e1-1173.e4. doi: 10.1016/j.cmi.2021.04.028. Epub 2021 May 3.
4
Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19.有新冠病毒疾病既往史的肾移植受者在接种第一剂基于信使核糖核酸的新冠病毒疫苗后产生强烈抗体反应。
Am J Transplant. 2021 Nov;21(11):3808-3810. doi: 10.1111/ajt.16764. Epub 2021 Jul 23.
5
Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.肾移植受者同源与异源第三剂疫苗接种后 4 周时的 SARS-CoV-2 抗体反应比较：一项随机临床试验。
JAMA Intern Med. 2022 Feb 1;182(2):165-171. doi: 10.1001/jamainternmed.2021.7372.
6
The Fourth Dose of CoronaVac Vaccine Results in a Small Increase of Seroconversion and Antibody Values Among Kidney Transplant Recipients.科兴新冠疫苗第四剂接种后，肾移植受者的血清转化率和抗体值略有上升。
Transplantation. 2022 Sep 1;106(9):e420-e421. doi: 10.1097/TP.0000000000004219. Epub 2022 Jun 14.
7
Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients.肾移植受者首次接种mRNA新冠疫苗后抗SARS-CoV-2抗体反应较弱。
Kidney Int. 2021 Jun;99(6):1487-1489. doi: 10.1016/j.kint.2021.03.014. Epub 2021 Mar 26.
8
Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration.肾移植受者在首次接种新冠疫苗后很少出现早期抗体反应。
Transplantation. 2021 Jul 1;105(7):e72-e73. doi: 10.1097/TP.0000000000003764.
9
Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).肾移植受者对 BNT162b2（辉瑞-生物科技）接种 SARS-CoV-2 疫苗的体液免疫反应受损。
Viruses. 2021 Apr 25;13(5):756. doi: 10.3390/v13050756.
10
Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients.肾移植受者对第三剂SARS-CoV-2 mRNA BNT162b2疫苗的抗体和T细胞反应。
Kidney Int. 2021 Dec;100(6):1337-1340. doi: 10.1016/j.kint.2021.09.014. Epub 2021 Oct 4.

引用本文的文献

1
Long-Term Immuno-Response and Risk of Breakthrough Infection After SARS-CoV-2 Vaccination in Kidney Transplantation.肾移植受者接种 SARS-CoV-2 疫苗后的长期免疫反应及突破性感染风险
Vaccines (Basel). 2025 May 26;13(6):566. doi: 10.3390/vaccines13060566.
2
Clinical outcomes in kidney transplant recipients receiving tixagevimab/cilgavimab for outpatient treatment of COVID-19: a single-center retrospective study.接受替沙格韦单抗/西加韦单抗门诊治疗新冠肺炎的肾移植受者的临床结局：一项单中心回顾性研究
Front Transplant. 2025 Jun 10;4:1579226. doi: 10.3389/frtra.2025.1579226. eCollection 2025.
3
The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based Analysis.疫苗接种频率对COVID-19公共卫生结果的影响：基于模型的分析。
Vaccines (Basel). 2025 Mar 30;13(4):368. doi: 10.3390/vaccines13040368.
4
Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective.四类免疫功能低下人群中发生重症新型冠状病毒肺炎的风险：法国专家观点
Infect Dis Ther. 2025 Apr;14(4):671-733. doi: 10.1007/s40121-025-01124-3. Epub 2025 Mar 18.
5
Immunosuppressive Therapy Modifies Anti-Spike IgG Subclasses Distribution After Four Doses of mRNA Vaccination in a Cohort of Kidney Transplant Recipients.免疫抑制疗法改变了一组肾移植受者在四剂 mRNA 疫苗接种后的抗刺突 IgG 亚类分布。
Vaccines (Basel). 2025 Jan 25;13(2):123. doi: 10.3390/vaccines13020123.
6
Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation.SARS-CoV-2 特异性记忆 B 细胞在增强免疫后促进实体器官移植免疫保护的作用。
Front Immunol. 2024 Oct 8;15:1463769. doi: 10.3389/fimmu.2024.1463769. eCollection 2024.
7
Immunogenicity and Predictive Factors Associated with Poor Response after Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Lung Transplant Patients.严重急性呼吸综合征冠状病毒2疫苗接种后肺移植患者免疫原性及与反应不佳相关的预测因素
Vaccines (Basel). 2024 Jul 22;12(7):822. doi: 10.3390/vaccines12070822.
8
Dietary Inulin to Improve SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients: The RIVASTIM-Inulin Randomised Controlled Trial.膳食菊粉改善肾移植受者对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的反应：RIVASTIM-菊粉随机对照试验
Vaccines (Basel). 2024 Jun 3;12(6):608. doi: 10.3390/vaccines12060608.
9
Immunogenicity and Safety of the Three-Dose COVID-19 Vaccine Regimen in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis.接受肾脏替代治疗患者的三剂新冠疫苗接种方案的免疫原性和安全性：一项系统评价和荟萃分析
Kidney Dis (Basel). 2024 Jan 19;10(2):107-117. doi: 10.1159/000536308. eCollection 2024 Apr.
10
Psoriasis and biological drugs at the time of SARS-CoV-2 infection: a mini review outlining risk of infection, seroprevalence, and safety and efficacy of the BNT162b2 vaccine.COVID-19 感染时的银屑病和生物药物：概述感染风险、血清流行率以及 BNT162b2 疫苗安全性和有效性的小型综述。
Front Immunol. 2024 Jan 30;15:1354729. doi: 10.3389/fimmu.2024.1354729. eCollection 2024.